PIK3CA and ductal breast carcinoma in situ: Our results indicating that DCIS cells with PIK3CA mutations possess a monoclonal structure in which expression modules are required specifically for proliferation pathways support previous findings and suggest that PIK3CA mutations alone should be included as a marker for predicting a lower risk of progression to IDC and for reassessment of treatment options.